Ranbaxy Innovation and Growth Focus

Research & Development: Overview Ranbaxy has an attractive portfolio of ANDAs and FTF pipeline Amongst the highest R&D spend in Indian Cos. Investment R&D Expense $ Mn 140 127 8.0% 120 110 104 7.0% 97 98 93 100 7% 6.0% 80 6% 6% 6% 5.0% 60 5% 4.0% 40 4% 20 3.0% 0 2.0% 2007 2008 2009 2010 2011 2012 R&D Expense $ Mn R&D Expense % of sales Over 1,100 R&D personnel with post graduate and scientific background People Dedicated facility for Gx Research Infrastructure Amongst the highest number of regulatory submissions on a cumulative basis internationally Amongst the most attractive FTF pipeline in the industry → Ability to monetize FTF opportunities in the past RANBAXY Trusted medicines.Healthier lives 20

View entire presentation